The University of Chicago Header Logo

Connection

Barry G. Arnason to Male

This is a "connection" page, showing publications Barry G. Arnason has written about Male.
Connection Strength

0.227
  1. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b. Mult Scler. 2010 Jan; 16(1):30-8.
    View in: PubMed
    Score: 0.019
  2. Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci. 2009 Feb 15; 277(1-2):150-4.
    View in: PubMed
    Score: 0.017
  3. Etretinate augments interferon beta-1b effects on suppressor cells in multiple sclerosis. Arch Neurol. 2001 Jan; 58(1):87-90.
    View in: PubMed
    Score: 0.010
  4. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019 04; 25(4):565-573.
    View in: PubMed
    Score: 0.008
  5. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996 Dec; 47(6):1463-8.
    View in: PubMed
    Score: 0.008
  6. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26.
    View in: PubMed
    Score: 0.007
  7. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65.
    View in: PubMed
    Score: 0.007
  8. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995 Dec; 45(12):2173-7.
    View in: PubMed
    Score: 0.007
  9. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71.
    View in: PubMed
    Score: 0.007
  10. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995 Jun; 45(6):1097-100.
    View in: PubMed
    Score: 0.007
  11. Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. J Neuroimmunol. 1993 Jul; 46(1-2):123-8.
    View in: PubMed
    Score: 0.006
  12. The hu-SCID myasthenic mouse. A new tool for the investigation of seronegative myasthenia gravis. Ann N Y Acad Sci. 1993 Jun 21; 681:303-5.
    View in: PubMed
    Score: 0.006
  13. Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study. J Neurol. 2013 Jul; 260(7):1838-45.
    View in: PubMed
    Score: 0.006
  14. Antibody-secreting cells to acetylcholine receptor and to presynaptic membrane receptor in seronegative myasthenia gravis. J Neuroimmunol. 1993 Mar; 43(1-2):145-9.
    View in: PubMed
    Score: 0.006
  15. Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. J Neuroimmunol. 1992 Feb; 36(2-3):171-7.
    View in: PubMed
    Score: 0.005
  16. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912.
    View in: PubMed
    Score: 0.005
  17. Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. Mult Scler. 2011 Dec; 17(12):1504-13.
    View in: PubMed
    Score: 0.005
  18. Interferon ß-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011 Apr 05; 76(14):1222-8.
    View in: PubMed
    Score: 0.005
  19. Olig1 is expressed in human oligodendrocytes during maturation and regeneration. Glia. 2011 Jun; 59(6):914-26.
    View in: PubMed
    Score: 0.005
  20. Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol. 1990 Apr; 27(4):366-72.
    View in: PubMed
    Score: 0.005
  21. Prevention of neural allograft rejection in the mouse following in vivo depletion of L3T4+ but not LYT-2+ T-lymphocytes. Prog Brain Res. 1990; 82:161-7.
    View in: PubMed
    Score: 0.005
  22. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97.
    View in: PubMed
    Score: 0.005
  23. Comparison of sympathetic skin response with quantitative sudomotor axon reflex test in diabetic neuropathy. Muscle Nerve. 1989 May; 12(5):420-3.
    View in: PubMed
    Score: 0.004
  24. Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
    View in: PubMed
    Score: 0.004
  25. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12.
    View in: PubMed
    Score: 0.004
  26. HLA antigens in narcolepsy. Neurology. 1987 Dec; 37(12):1858-60.
    View in: PubMed
    Score: 0.004
  27. Multiple sclerosis: activated cells in cerebrospinal fluid in acute exacerbations. Ann Neurol. 1985 Dec; 18(6):722-5.
    View in: PubMed
    Score: 0.004
  28. Effect of myasthenia serum and anti-acetylcholine receptor monoclonal antibody on the distributions of T-cell subsets in myasthenia patients and normal subjects. Asian Pac J Allergy Immunol. 1985 Jun; 3(1):30-6.
    View in: PubMed
    Score: 0.003
  29. Multiple sclerosis: relation of in vitro IgG secretion to T suppressor cell number and function. Neurology. 1984 Sep; 34(9):1155-60.
    View in: PubMed
    Score: 0.003
  30. Neuropathy accompanying IgM lambda monoclonal gammopathy. Acta Neuropathol. 1983; 59(4):255-61.
    View in: PubMed
    Score: 0.003
  31. Oligoclonal IgG in rabbits with experimental allergic encephalomyelitis: non-reactivity of the bands with sensitizing neural antigens. Neurochem Res. 1982 Oct; 7(10):1209-21.
    View in: PubMed
    Score: 0.003
  32. A biochemically distinct sub-population of neurons in the human substantia gelatinosa. Study with G-6-PD histochemistry. J Neurol Sci. 1982 Aug; 55(2):175-83.
    View in: PubMed
    Score: 0.003
  33. Muscle acid protease activity in amyotrophic lateral sclerosis: correlation with clinical and pathologic features. Neurology. 1982 Aug; 32(8):901-3.
    View in: PubMed
    Score: 0.003
  34. The effect of short-term and chronic immunosuppression on Theiler's virus demyelination. J Neuroimmunol. 1982 Jun; 2(3-4):223-34.
    View in: PubMed
    Score: 0.003
  35. Multiple sclerosis: current concepts and management. Hosp Pract (Off Ed). 1982 Feb; 17(2):81-9.
    View in: PubMed
    Score: 0.003
  36. The absence of unique kainic acid-like molecules in urine, serum, and CSF from Huntington's disease patients. J Neurol Sci. 1981 Sep; 51(3):355-60.
    View in: PubMed
    Score: 0.003
  37. Cerebrospinal fluid and serum oligoclonal IgG bands in rabbits with experiment allergic encephalomyelitis. Neurochem Res. 1981 Jan; 6(1):87-96.
    View in: PubMed
    Score: 0.002
  38. Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology. 1979 Mar; 29(3):291-6.
    View in: PubMed
    Score: 0.002
  39. Cellular immunity in myasthenia gravis. Response to purified acetylcholine receptor and autologous thymocytes. N Engl J Med. 1976 Mar 25; 294(13):694-8.
    View in: PubMed
    Score: 0.002
  40. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996 Jan; 46(1):12-8.
    View in: PubMed
    Score: 0.002
  41. Suppression of experimental allergic encephalomyelitis in guinea-pigs with poly-L-lysine. Clin Exp Immunol. 1975 Dec; 22(3):539-45.
    View in: PubMed
    Score: 0.002
  42. Tumor growth: suppression in mice by submanidibular gland extirpation. J Natl Cancer Inst. 1975 Nov; 55(5):1203-5.
    View in: PubMed
    Score: 0.002
  43. Neutralizing antibodies to poliovirus and mumps virus in amyotrophic lateral sclerosis. J Neurol Sci. 1974 Dec; 23(4):537-40.
    View in: PubMed
    Score: 0.002
  44. Histocompatibility types and measles antibodies in multiple sclerosis and optic neuritis. J Neurol Sci. 1974 Aug; 22(4):419-28.
    View in: PubMed
    Score: 0.002
  45. Peripheral nerve segmental demyelination induced by intraneural diphtheria toxin injection. Sodium Na 24 and carbon 14-labeled inulin kinetics in diphtheria toxin-injected nerve and the effect of hydrocortisone. Arch Neurol. 1974 Feb; 30(2):163-8.
    View in: PubMed
    Score: 0.002
  46. The human-severe combined immunodeficiency myasthenic mouse model: a new approach for the study of myasthenia gravis. Ann Neurol. 1993 Jul; 34(1):48-56.
    View in: PubMed
    Score: 0.001
  47. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol. 1991 Apr; 32(1):67-74.
    View in: PubMed
    Score: 0.001
  48. Beta-adrenergic receptors on splenic lymphocytes from axotomized mice. Int J Immunopharmacol. 1984; 6(3):171-7.
    View in: PubMed
    Score: 0.001
  49. The thymus gland in elderly patients with myasthenia gravis. Neurology. 1975 Mar; 25(3):294-5.
    View in: PubMed
    Score: 0.000
  50. Parainfluenza, histocompatibility, and multiple sclerosis. Association of parainfluenza antibodies and histocompatibility types in MS and optic neuritis. Arch Neurol. 1974 Apr; 30(4):327-9.
    View in: PubMed
    Score: 0.000
  51. The role of thymectomy in the treatment of myasthenia gravis. Ann N Y Acad Sci. 1971 Sep 15; 183:308-15.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.